Management of scleroderma.
D062365:Aminobenzoates / Q000627:therapeutic use; D000614:Aminocaproates / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D004121:Dimethyl Sulfoxide / Q000627:therapeutic use; D004777:Environment; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D009747:Nutritional Physiological Phenomena; D010396:Penicillamine / Q000627:therapeutic use*; D010810:Physical and Rehabilitation Medicine; D011374:Progesterone / Q000627:therapeutic use; D012065:Relaxin / Q000627:therapeutic use; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000534:rehabilitation / Q000628:therapy; D014665:Vasodilator Agents / Q000627:therapeutic use*
D062365:Aminobenzoates; D000614:Aminocaproates; D000893:Anti-Inflammatory Agents; D006728:Hormones; D007166:Immunosuppressive Agents; D014665:Vasodilator Agents; D011374:Progesterone; D012065:Relaxin; D010396:Penicillamine; D004121:Dimethyl Sulfoxide